This Elonva market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the rising prevalence of testis and ovary disorders, the growing adoption of effective medications such as selective estrogen receptor modulators (SERMs) and selective androgen receptor modulators (SARMs), the increasing use of hormone replacement therapy, greater awareness, higher healthcare expenditure, and advancements in technology and new drug developments.
The projected growth for the forecast period is driven by rising infertility rates globally, increased awareness and social acceptance of fertility treatments, the growing trend of delayed motherhood, higher healthcare spending, and the impact of modern lifestyle factors such as stress and diet. Key trends expected in the forecast period include the development of novel therapies and personalized medicine, progress in assisted reproductive technologies, the introduction and acceptance of biosimilars in fertility treatments, the adoption of telemedicine and digital health platforms, and a focus on sustainability in pharmaceutical manufacturing.
The increasing prevalence of ovarian disorders is expected to drive the growth of the elonva market. Ovarian disorders can be caused by various factors, such as hormonal imbalances, genetic mutations (e.g., BRCA1 and BRCA2), polycystic ovary syndrome (PCOS), autoimmune conditions, exposure to environmental toxins, and lifestyle choices such as obesity and smoking. Elonva is used to treat ovarian disorders by stimulating the ovaries to produce multiple follicles, enhancing the chances of successful pregnancy in women experiencing fertility issues, including PCOS and unexplained infertility. For example, in 2024, the American Cancer Society reported 19,680 new ovarian cancer cases and 12,740 related deaths in the U.S. As such, the rising prevalence of ovarian disorders is contributing to the growth of the elonva market.
The increasing infertility rates are expected to drive the growth of the elonva market. Infertility refers to the inability to conceive after 12 months of regular, unprotected sexual intercourse. Rising infertility rates are attributed to factors such as delayed childbearing, lifestyle changes, environmental toxins, and health conditions such as obesity and diabetes. Elonva helps by improving ovarian stimulation through a single injection, encouraging the ovaries to produce multiple follicles, thus improving the chances of a successful pregnancy for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF). In April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or one in six individuals, faces infertility. This rising infertility rate is fueling the growth of the elonva market.
A key trend in the elonva market is the expansion of its use for treating platinum-resistant ovarian cancer and supporting assisted reproductive technology (ART). This trend aims to address the demand for advanced therapies for patients with platinum-resistant ovarian cancer, which is often difficult to treat. In January 2023, Merck & Co., Inc. received European Commission approval for Elonva to be used for controlled ovarian stimulation (COS) in women undergoing ART. This approval standardizes labeling across all European Union member states, simplifying access for healthcare providers and patients. Elonva is significant for its ability to replace the first seven daily injections of conventional follicle-stimulating hormone (FSH) with a single subcutaneous injection, reducing the treatment burden for women trying to conceive.
The key company operating in the elonva market is Merck & Co. Inc.
North America was the largest region in the elonva market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elonva report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elonva market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elonva (corifollitropin alfa) is a fertility medication used in assisted reproductive treatments such as in vitro fertilization (IVF) to stimulate the ovaries and promote the growth of multiple follicles. It is a long-acting formulation that requires only a single injection to start ovarian stimulation, reducing the need for daily hormone injections. This approach offers a more controlled and convenient method for ovarian stimulation, increasing the chances of a successful pregnancy in women facing fertility challenges.
The primary clinical indications for elonva include in vitro fertilization (IVF), treatment of hypogonadotropic hypogonadism in adolescent males, and the management of ovarian hyperstimulation syndrome (OHSS). IVF is a procedure that helps individuals and couples conceive by fertilizing an egg with sperm outside the body in a laboratory. Elonva is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used in fertility clinics, hospitals, research institutes, and other medical settings.
The elonva market research report is one of a series of new reports that provides elonva market statistics, including elonva industry global market size, regional shares, competitors with an elonva market share, detailed elonva market segments, market trends, and opportunities, and any further data you may need to thrive in the elonva industry. This elonva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The elonva market consists of sales of corifollitropin alfa injectable formulations and hormonal combination treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the rising prevalence of testis and ovary disorders, the growing adoption of effective medications such as selective estrogen receptor modulators (SERMs) and selective androgen receptor modulators (SARMs), the increasing use of hormone replacement therapy, greater awareness, higher healthcare expenditure, and advancements in technology and new drug developments.
The projected growth for the forecast period is driven by rising infertility rates globally, increased awareness and social acceptance of fertility treatments, the growing trend of delayed motherhood, higher healthcare spending, and the impact of modern lifestyle factors such as stress and diet. Key trends expected in the forecast period include the development of novel therapies and personalized medicine, progress in assisted reproductive technologies, the introduction and acceptance of biosimilars in fertility treatments, the adoption of telemedicine and digital health platforms, and a focus on sustainability in pharmaceutical manufacturing.
The increasing prevalence of ovarian disorders is expected to drive the growth of the elonva market. Ovarian disorders can be caused by various factors, such as hormonal imbalances, genetic mutations (e.g., BRCA1 and BRCA2), polycystic ovary syndrome (PCOS), autoimmune conditions, exposure to environmental toxins, and lifestyle choices such as obesity and smoking. Elonva is used to treat ovarian disorders by stimulating the ovaries to produce multiple follicles, enhancing the chances of successful pregnancy in women experiencing fertility issues, including PCOS and unexplained infertility. For example, in 2024, the American Cancer Society reported 19,680 new ovarian cancer cases and 12,740 related deaths in the U.S. As such, the rising prevalence of ovarian disorders is contributing to the growth of the elonva market.
The increasing infertility rates are expected to drive the growth of the elonva market. Infertility refers to the inability to conceive after 12 months of regular, unprotected sexual intercourse. Rising infertility rates are attributed to factors such as delayed childbearing, lifestyle changes, environmental toxins, and health conditions such as obesity and diabetes. Elonva helps by improving ovarian stimulation through a single injection, encouraging the ovaries to produce multiple follicles, thus improving the chances of a successful pregnancy for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF). In April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or one in six individuals, faces infertility. This rising infertility rate is fueling the growth of the elonva market.
A key trend in the elonva market is the expansion of its use for treating platinum-resistant ovarian cancer and supporting assisted reproductive technology (ART). This trend aims to address the demand for advanced therapies for patients with platinum-resistant ovarian cancer, which is often difficult to treat. In January 2023, Merck & Co., Inc. received European Commission approval for Elonva to be used for controlled ovarian stimulation (COS) in women undergoing ART. This approval standardizes labeling across all European Union member states, simplifying access for healthcare providers and patients. Elonva is significant for its ability to replace the first seven daily injections of conventional follicle-stimulating hormone (FSH) with a single subcutaneous injection, reducing the treatment burden for women trying to conceive.
The key company operating in the elonva market is Merck & Co. Inc.
North America was the largest region in the elonva market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elonva report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elonva market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elonva (corifollitropin alfa) is a fertility medication used in assisted reproductive treatments such as in vitro fertilization (IVF) to stimulate the ovaries and promote the growth of multiple follicles. It is a long-acting formulation that requires only a single injection to start ovarian stimulation, reducing the need for daily hormone injections. This approach offers a more controlled and convenient method for ovarian stimulation, increasing the chances of a successful pregnancy in women facing fertility challenges.
The primary clinical indications for elonva include in vitro fertilization (IVF), treatment of hypogonadotropic hypogonadism in adolescent males, and the management of ovarian hyperstimulation syndrome (OHSS). IVF is a procedure that helps individuals and couples conceive by fertilizing an egg with sperm outside the body in a laboratory. Elonva is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used in fertility clinics, hospitals, research institutes, and other medical settings.
The elonva market research report is one of a series of new reports that provides elonva market statistics, including elonva industry global market size, regional shares, competitors with an elonva market share, detailed elonva market segments, market trends, and opportunities, and any further data you may need to thrive in the elonva industry. This elonva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The elonva market consists of sales of corifollitropin alfa injectable formulations and hormonal combination treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Elonva Market Characteristics4. Elonva Market Trends and Strategies5. Elonva Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Elonva Pricing Analysis & Forecasts30. Global Elonva Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Elonva Market32. Recent Developments in the Elonva Market
3. Elonva Market Biologic Drug Characteristics
6. Global Elonva Growth Analysis and Strategic Analysis Framework
8. Elonva Market Segmentation
9. Global Elonva Epidemiology of Clinical Indications
10. Elonva Market Regional and Country Analysis
11. Asia-Pacific Elonva Market
12. China Elonva Market
13. India Elonva Market
14. Japan Elonva Market
15. Australia Elonva Market
16. South Korea Elonva Market
17. Western Europe Elonva Market
18. UK Elonva Market
19. Germany Elonva Market
20. France Elonva Market
21. Eastern Europe Elonva Market
22. North America Elonva Market
23. USA Elonva Market
24. Canada Elonva Market
25. South America Elonva Market
26. Middle East Elonva Market
27. Africa Elonva Market
28. Elonva Market Competitive Landscape and Company Profiles
29. Global Elonva Market Pipeline Analysis
33. Elonva Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Elonva Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on elonva market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elonva? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The elonva market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: in Vitro Fertilization (IVF); Hypogonadotropic Hypogonadism in Adolescent Males; Ovarian Hyperstimulation Syndrome (OHSS) Management2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by End User: Fertility Clinics; Hospitals; Research Institutes; Other End Users
Key Companies Mentioned: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
